Molecular profiling of small bowel adenocarcinoma for personalized treatment
Official title: Molecularly Redefining Small Bowel Adenocarcinoma to Accelerate Precision Patient Care
Run by Copenhagen University Hospital at Herlev · NCT06234306 · Data updated 2026-11-12
This study is trying to find specific markers in small bowel adenocarcinoma to help create personalized treatment plans for patients with this rare cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Copenhagen University Hospital at Herlev Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy |
| Locations | 3 sites (Aarhus N, Denmark and 2 other locations) |
| Status | Recruiting |
| Started | January 1, 2024 |
| Main results expected | December 31, 2033 |
| Study ends | December 31, 2033 |
| Registry record updated | October 23, 2026 |
| Trial ID | NCT06234306 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults over 18 years with histologically verified small bowel adenocarcinoma.
✕Probably not a fit
Patients who do not have sufficient material for molecular testing or who have opted out of using their biological material for research may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on small bowel adenocarcinoma, a rare cancer with limited understanding of its molecular characteristics and optimal management. The study aims to identify prognostic and predictive biomarkers through comprehensive molecular characterization, including DNA, RNA, and T-cell receptor sequencing. By developing consensus molecular subtypes, the research seeks to inform tailored treatment strategies, potentially improving patient outcomes. The findings could lay the groundwork for future clinical trials and personalized medicine approaches for this specific patient group.
Why it matters
Potential benefit: If successful, this study could lead to more effective, personalized treatment options for patients with small bowel adenocarcinoma.
How similar studies have gone: While small bowel adenocarcinoma is a rare condition, similar approaches in other cancers have shown promise in identifying molecular subtypes and improving treatment outcomes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: Patients with histologically verified small bowel adenocarcinoma Patients older than 18 years Exclusion criteria: Insufficient material for molecular testing Patients registered in Vævsanvendelsesregistret\& Vævsanvendelsesregistret; refers to a central Danish registry where patients can opt out of allowing their biological material to be used for purposes other than their own disease management.
Where it's running
-
Department of Oncology, Aarhus University Hospital
Aarhus N, Denmark, Denmark Recruiting -
Department Surgical Gastroenterology, Copenhagen University Hospital - Rigshospitalet
Copenhagen Ø, Denmark, Denmark Recruiting -
Department of Oncology Copenhagen University Hospital - Herlev and Gentofte
Herlev, Denmark, Denmark Recruiting
Study contacts
- Principal investigator: Dan Høgdall, MD PhD — Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte
- Study coordinator: Dan Høgdall, MD PhD
- Email: danhog01@regionh.dk
- Phone: 004538681954
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Paclitaxel given inside the abdomen with systemic therapy for GI cancers with peritoneal spread
This phase II study tests a combination of intraperitoneal and systemic chemotherapy (paclitaxel) in adults with digestive tract cancers that have spread to the peritoneum.
-
Capsule camera screening of the small intestine for people with Lynch syndrome
This project looks back at past small-bowel capsule endoscopy exams to see if they detect precancerous lesions or early cancer in people with Lynch syndrome.
-
GUCY2C prime-boost vaccine for advanced colorectal and small bowel adenocarcinomas
This trial will try a two-step GUCY2C vaccine approach (an adenovirus prime followed by two Listeria-based boosts) in adults with advanced colorectal or small bowel adenocarcinomas that have progressed after standard treatments.
-
Treatment for advanced small bowel tumors using NALIRIFOX
This study tests a new combination treatment called NALIRIFOX to see if it can help people with advanced small bowel tumors feel better and manage their disease.
-
Dostarlimab treatment for advanced or metastatic cancers with specific genetic markers
This study is testing if the immunotherapy dostarlimab can help people with certain advanced cancers that have specific genetic markers feel better compared to standard chemotherapy.
-
Using videocapsule endoscopy to detect small bowel cancer in Lynch syndrome patients
This study is testing whether a tiny camera capsule can help find small bowel cancer in people with Lynch syndrome.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.